SCHEMBL2984464

SCHEMBL2984464

CC1(c2ccccc2)C(=O)C=C1O

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 3/20 0.48
MMP9 P14780 3/20 0.48
HCAR2 Q8TDS4 4/20 0.43
HCAR3 P49019 2/20 0.43
CYP1A2 P05177 1/20 0.43
MMP3 P08254 1/20 0.36
MMP8 P22894 1/20 0.36
MMP13 P45452 1/20 0.36
SIRT1 Q96EB6 1/20 0.36
HTR6 P50406 2/20 0.35
TSHR P16473 1/20 0.35
ALDH1A1 P00352 1/20 0.34
POLB P06746 1/20 0.34
GPR55 Q9Y2T6 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2992368 0.68 MMP2 (0.42) MMP2MMP9HCAR2HCAR3CYP1A2
SCHEMBL29794093 0.67 MMP2 (0.54) MMP2MMP9MMP3MMP8MMP13
SCHEMBL3284760 0.67 MMP2 (0.54) MMP2MMP9CYP1A2MMP3MMP8
SCHEMBL4495622 0.67 ALDH1A1 (0.46) MMP2MMP9HCAR2HCAR3CYP1A2
SCHEMBL4503649 0.67 HCAR2 (0.51) MMP2MMP9HCAR2HCAR3CYP1A2
SCHEMBL4495628 0.67 ALDH1A1 (0.46) MMP2MMP9HCAR2HCAR3CYP1A2
SCHEMBL4500250 0.67 HCAR2 (0.51) MMP2MMP9HCAR2HCAR3CYP1A2
SCHEMBL4507630 0.67 ALDH1A1 (0.46) MMP2MMP9HCAR2HCAR3CYP1A2
SCHEMBL4500703 0.67 HCAR2 (0.51) MMP2MMP9HCAR2HCAR3CYP1A2
SCHEMBL77738 0.65 MMP2 (1.00) MMP2MMP9MMP3MMP8MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7786177-B2 Phenylalanine enamide derivatives UCB PHARMA S.A. (BE) 2010-08-31 US disclosed
US-7645770-B2 Phenylalanine enamide derivatives UCB PHARMA S.A. (BE) 2010-01-12 US disclosed
US-20090186914-A1 Phenylalanine Enamide Derivatives UCB PHARMA, S.A. (BE) 2009-07-23 US disclosed
US-7531549-B2 Phenylalanine enamide derivatives UCB PHARMA, S.A. (BE) 2009-05-12 US disclosed
US-20090105291-A1 Phenylalanine Enamide Derivatives RIGEL PHARMACEUTICALS, INC. (US) 2009-04-23 US disclosed
US-7501437-B2 Phenylalanine enamide derivatives UCB PHARMA, S.A. (BE) 2009-03-10 US disclosed
US-20070167483-A1 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders UCB PHARMA S.A. (BE) 2007-07-19 US disclosed
EP-1780201-A2 PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS Celltech R&D Limited (GB) 2007-05-02 EP disclosed
US-20070027174-A1 Phenylalanine Enamide Derivatives CELLTECH R&D LIMITED 2007-02-01 US disclosed
US-7122556-B2 Phenylalanine enamide derivatives CELLTECH R&D LIMITED (GB) 2006-10-17 US disclosed
US-6878718-B2 Phenylalanine enamide derivatives CELLTECH R&D LIMITED (GB) 2005-04-12 US disclosed
US-20050038084-A1 Phenylalanine enamide derivatives CELLTECH R&D LIMITED 2005-02-17 US disclosed
EP-1370531-A1 PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS Celltech R & D Limited (GB) 2003-12-17 EP disclosed
US-20020169336-A1 Phenylalanine enamide derivatives UCB PHARMA S.A. (BE) 2002-11-14 US disclosed
WO-2002068393-A1 PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS CELLTECH R & D LIMITED (GB) 2002-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027174-A1 Phenylalanine Enamide Derivatives PAH, HRH3, AGTR2 MMP2 1632/4885MMP9 1894/4885HCAR2 150/4885
US-20090105291-A1 Phenylalanine Enamide Derivatives PAH, HRH3, PRLHR MMP2 1510/4885MMP9 1676/4885HCAR2 140/4885
US-20050038084-A1 Phenylalanine enamide derivatives PAH, ARRB1, ACVR2B MMP2 1677/4885MMP9 1896/4885HCAR2 190/4885
US-20020169336-A1 Phenylalanine enamide derivatives CCR1, AHR, PAH MMP2 1702/4885MMP9 1881/4885HCAR2 102/4885
US-20070167483-A1 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders ITGB2, VCAM1, ITGB1 MMP2 1696/4885MMP9 1447/4885HCAR2 78/4885
US-20090186914-A1 Phenylalanine Enamide Derivatives PAH, HRH3, PRLHR MMP2 1510/4885MMP9 1676/4885HCAR2 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.